ポンペ病治療の世界市場2016-2020

◆英語タイトル:Global Pompe Disease Treatment Market 2016-2020
◆商品コード:IRTNTR11105
◆発行会社(調査会社):Technavio
◆発行日:2016年12月13日
◆ページ数:65
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、ポンペ病治療の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、ポンペ病治療の世界市場規模及び予測、種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Pompe Disease Treatment
Lysosomal storage diseases (LSDs) are a group of progressive, autosomal recessive, and hereditary disorders characterized by the accumulation of specific substrates and variable age of onset and clinical symptoms. Pompe disease, a type of LSD, is caused by mutations in the GAA gene. These mutations inhibit the mechanism of action (MOA) of GAA; it is an enzyme responsible for catabolizing glycogen, resulting in accumulation of glycogen to toxic levels in the lysosomes of the cells. The buildup of glycogen in certain tissues and organs, especially in the muscles, hinders the normal functions of the organs. It can be further divided as adult-onset and infantile-onset Pompe diseases. As the disease is an autosomal recessive hereditary disorder, both parents are carriers and pass one copy of the mutated gene to their offspring. It affects both women and men across all ethnicities and races and has a varied age of onset of symptoms. Till date, researchers have identified over 300 genetic mutation types that lead to disease manifestation. Though there is no known cure for Pompe disease, enzyme replacement therapy (ERT) and diet therapy have been effective in reducing its clinical manifestations.

Technavio’s analysts forecast the global Pompe disease treatment market to grow at a CAGR of 11.85% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global Pompe disease treatment market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of the drugs available in the market and the drug candidates that are in various phases of development for the treatment of Pompe disease.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Pompe Disease Treatment Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Amicus Therapeutics
• Audentes Therapeutics
• Sanofi Genzyme

[Other prominent vendors]
• EpiVax
• Oxyrane
• Sangamo BioSciences
• Valerion Therapeutics

[Market driver]
• Special regulatory drug designations for orphan drugs
• For a full, detailed list, view our report

[Market challenge]
• Limited patient population
• For a full, detailed list, view our report

[Market trend]
• Emergence of immunotherapy for Pompe disease
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

Table of Contents
PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Symptoms
• Diagnosis
• Etiology and pathogenesis
• Biochemical pathway
• Epidemiology
• Management
• Economic burden

PART 06: Market landscape
• Market overview
• Five forces analysis

PART 07: Market segmentation by type of Pompe disease

PART 08: Geographical segmentation
• Pompe disease treatment market in EMEA
• Pompe disease treatment market in Americas
• Pompe disease treatment market in US
• Pompe disease treatment market in APAC

PART 09: Market drivers
• Special regulatory drug designations for orphan drugs
• Reimbursement policies for treatment
• Designated under ICD-10 code
• Shorter development timelines

PART 10: Impact of drivers

PART 11: Market challenges
• Limited patient population
• Weak pipeline
• Lack of long-term commitment

PART 12: Impact of drivers and challenges

PART 13: Market trends
• Focus on gene therapy
• Emergence of immunotherapy for Pompe disease
• Growing public awareness

PART 14: Vendor landscape
• Competitive scenario
• Other prominent vendors

PART 15: Key vendor analysis
• Amicus Therapeutics
• Audentes Therapeutics
• Sanofi Genzyme

PART 16: Appendix
• List of abbreviations

PART 17: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Approved drugs for Pompe disease
Exhibit 03: Snapshot of Pompe disease
Exhibit 04: Signs and symptoms of Pompe disease
Exhibit 05: Differential diagnosis of Pompe diseases in infants
Exhibit 06: Differential diagnosis of Pompe diseases in adults and children
Exhibit 07: Biochemical pathway of Pompe disease
Exhibit 08: Approaches used in treating Pompe disease
Exhibit 09: Snapshot of global Pompe disease treatment market 2015
Exhibit 10: Market overview of global Pompe disease treatment market
Exhibit 11: Opportunity analysis in developed and emerging markets
Exhibit 12: Global Pompe disease treatment market 2015-2020 ($ millions)
Exhibit 13: Five forces analysis
Exhibit 14: Market segmentation by type of Pompe disease
Exhibit 15: Snapshot of global Pompe disease treatment market by geography
Exhibit 16: Global Pompe disease treatment market segmentation by geography 2015-2020 ($ millions)
Exhibit 17: Overview of Pompe disease treatment market in EMEA
Exhibit 18: Prevalence rates of Pompe disease (per 100,000) in EMEA 2015
Exhibit 19: Incentives provided for orphan drugs by EU regulation
Exhibit 20: Pompe disease treatment market in EMEA 2015-2020 ($ millions)
Exhibit 21: Overview of Pompe disease treatment market in Americas
Exhibit 22: Prevalence rates of Pompe disease (one in 100,000) in Americas 2015
Exhibit 23: Orphan drug development and regulatory challenges
Exhibit 24: Pompe disease treatment market in Americas 2015-2020 ($ millions)
Exhibit 25: Incentives provided for orphan drugs by US regulation
Exhibit 26: Pompe disease treatment market in US 2015-2020 ($ millions)
Exhibit 27: Overview of Pompe disease treatment market in APAC
Exhibit 28: Prevalence rates of Pompe disease (one in 100,000) in APAC
Exhibit 29: Incentives provided for orphan drugs by Japanese regulation
Exhibit 30: Incentives provided for orphan drugs by Australian regulation
Exhibit 31: Pompe disease treatment market in APAC 2015-2020 ($ millions)
Exhibit 32: US FDA filed to approved time: Orphan drugs versus non-orphan drugs (median time)
Exhibit 33: Impact of drivers
Exhibit 34: Pipeline for Pompe disease treatment 2016
Exhibit 35: Pipeline molecules being developed for the treatment of Pompe disease
Exhibit 36: Pompe disease drugs discontinued from development
Exhibit 37: Impact of drivers and challenges
Exhibit 38: Competitive structure analysis of global Pompe disease treatment market 2015
Exhibit 39: Region-wise combined sales of Myozyme and Lumizyme 2013-2015 ($ millions)
Exhibit 40: Amicus Therapeutics: Key highlights
Exhibit 41: Amicus Therapeutics: Strength assessment
Exhibit 42: Amicus Therapeutics: Strategy assessment
Exhibit 43: Amicus Therapeutics: Opportunity assessment
Exhibit 44: Audentes Therapeutics: Profile
Exhibit 45: Audentes Therapeutics: Strength assessment
Exhibit 46: Audentes Therapeutics: Strategy assessment
Exhibit 47: Audentes Therapeutics: Opportunity assessment
Exhibit 48: Sanofi Genzyme: Key highlights
Exhibit 49: Sanofi Genzyme: Strength assessment
Exhibit 50: Sanofi Genzyme: Strategy assessment
Exhibit 51: Sanofi Genzyme: Opportunity assessment



【掲載企業】

Amicus Therapeutics, Audentes Therapeutics, Sanofi-Genzyme, EpiVax, Oxyrane, Sangamo BioSciences, Valerion Therapeutics.

【レポートのキーワード】

ポンペ病治療、ポンペ病、リソソーム蓄積症

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[ポンペ病治療の世界市場2016-2020] (コード:IRTNTR11105)販売に関する免責事項を必ずご確認ください。
★調査レポート[ポンペ病治療の世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆